RXRX Price Prediction Next Week
Analysis and Insights
Based on the analysis of news sentiment and technical indicators, here is the prediction for Recursion Pharmaceuticals (RXRX) stock price for the next trading week:
News Sentiment and Catalysts:
- Bullish Sentiment: Recent purchases by Cathie Wood's ARK Investment, including 35,000 shares, indicate strong institutional confidence in RXRX's potential.
- Option Flow: High call option volume (13,931 contracts) and a low Put/Call Ratio of 0.08 suggest positive market sentiment ahead of earnings on May 8th.
- Analyst Recommendations: A strong buy recommendation with an average analyst target price of $9.00, representing a 48.51% upside from the current price.
Technical Analysis:
- RSI: The Relative Strength Index (RSI) for RXRX is at 40.12, indicating the stock is near oversold territory and potentially undervalued.
- MACD: The MACD line is slightly below the signal line, but the histogram shows a bullish divergence, suggesting a potential trend reversal.
- Bollinger Bands: The stock is trading near the lower Bollinger Band, indicating potential overselling and a possible bounce.
- Fibonacci Levels: The stock is trading above the pivot level of $6.64, with resistance levels at $7.47 and $7.98, and support at $5.82.
Price Prediction:
- Target Price: Based on the bullish sentiment, technical indicators, and analyst targets, the stock is expected to reach $8.20 in the next trading week.
- Recommendation: Buy, as the stock is likely to break through the resistance levels and move higher.
RXRX Similar Chart Price Prediction
The price of RXRX is predicted to go up 21.03%, based on the high correlation periods with XOS. The similarity of these two price pattern on the periods is 97.61%.
RXRX
XOS
Up: 21.03%Similarity: 97.61%
RXRX Revenue Forecast
RXRX EPS Forecast
RXRX FAQs
What is RXRX revenue forecast for next quarter？
What is RXRX eps forecast for next quarter？
RXRX Analyst's Forecast
Scott Schoenhaus
Keybanc
Buy
2025-01-08
Price Target
$12 → $10
Upside
+37.74%
KeyBanc lowered the firm's price target on Recursion Pharmaceuticals to $10 from $12 and keeps an Overweight rating on the shares. The firm notes healthcare technology stocks were under pressure for most of last year but saw a rebound in the last two months following the Trump election. In combination with consensus estimate cuts since the middle of last year, KeyBanc sees attractive buying opportunities in the space in 2025. From a valuation multiple perspective, the firm believes companies with healthy balance sheets and steady free cash flow profiles will see less risk to multiple contraction, even with more modest growth trends. Conversely, it sees the most risk for companies that have challenged balance sheets and limited profitability in the near and longer term.
